Figure 4. (A) HEK-293 cells were treated with HGF, and total protein lysates were immunoassayed to detect expression levels of PXN, DRP-1, MFN-2, phospho-DRP 616, phospho-DRP 637, total BCL-2, and phospho-BCL-2. (B) BCL-2 was immunoprecipitated and then blotted for PXN to assess association between BCL-2 and PXN. These blots show wild-type and mutant PXN binding to BCL-2 and their association with DRP-1 and MFN-2 in response to HGF treatment. The BCL-2 blot shows levels of BCL-2 immunoprecipitated from each sample.